Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 11 Dec 2024
In 1982, two Australian physician-scientists discovered a spiral-shaped bacterium whose form not only dictated function, but its capacity to dwell in the human body's harshest chemical environment. These two clues would help ...
Read Full NewsA nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.
Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge